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Background: With a decrease in heroin’s purity and availability in the European drug
market, Hungarian opioid dependent patients started to substitute heroin with novel
psychoactive substances (NPS) and especially with synthetic cathinones.
Goal: This study aims to assess whether clients of opioid substitution treatment (OST)
with and without a history of synthetic cathinone use during therapy differ in (1) the
rate and type of experienced childhood trauma, (2) the way they cope with negative
life events, (3) their motivation to change substance use behavior, (4) the rate of
treatment retention.
Methods: A total of 198 clients of an outpatient centers (Nyírõ Gyula National Institute
of Psychiatry and Addictions, Budapest) OST were asked to provide information about
their general substance use experiences, including the consumption of NPS during
treatment, their childhood traumatic experiences (Childhood Trauma Questionnaire),
cognitive emotion regulation strategies (Cognitive Emotion Regulation Questionnaire),
their motivation to change substance use behavior (University of Rhode Island Change
Assessment Scale) and current psychiatric symptoms (Brief Symptom Inventory).
Baseline data was collected in the summer of 2015, while 4 years follow-up data on
treatment retention was obtained in the summer of 2019.
Results: The majority of the clients were male (N = 141, 71.2%), receiving methadone
as a substitute for opioids (N = 178, 89.9%), while mean age of the full sample was
39.7 (SD = 6.8). Based on a logistic regression model, the odds for past year synthetic
cathinone use was higher among clients with more severe psychiatric symptoms
(B = 0.8, OR = 2.2, p < 0.01) and among clients who were in treatment for a shorter
period of time (B = 0.1, OR = 0.9, p < 0.05). Synthetic cathinone use during treatment
was further associated with less adaptive strategies to cope with negative life events.
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Synthetic cathinone use was also a risk factor for reduced treatment retention (B =−0.8,
OR = 0.4, p < 0.05) and was associated with lower odds of being member of a latent
class with less severe psychopathological profile (B = −0.9, OR = 0.4, p < 0.05).
Conclusion: Synthetic cathinone use during treatment is associated with poorer
treatment outcomes and might be characterized by more severe psychiatric symptoms
and amotivation to change substance use among opioid dependent clients.
Keywords: NPS, synthetic cathinone, opioid substitution therapy, trauma, emotion regulation
INTRODUCTION
Considering the ever-changing world of contemporary drug
scene, the past two decades were characterized by the
emergence of NPS, started with the appearance of SC, as
first reported in the early 2000s (Urquhart, 2004). Cathinone-
derivatives, such as mephedrone, 4-MEC, methylone, pentedrone
or MDPV became popular alternates of formerly scheduled
psychostimulants and even depressants (e.g., opioids). Regular
SC users usually attributed their consumptive choices to easy
availability, perception of safety, low prices and pleasurable drug
effects (e.g., Van Hout and Brennan, 2012). Although most
countries have implemented some forms of control legislations,
varying in their type or depth (Corazza and Roman-Urrestarazu,
2018), online trafficking that provides relative anonymity for
NPS users (EMCDDA, 2016) and the fact that NPS consumption
is now an integral part of the drug scene still support SC
popularity among members of certain subpopulations (such as
club-goers, prisoners, psychiatric patients, and injecting drug
users). Based on the results of the European Syringe Collection
and Analysis Project Enterprise (ESCAPE) 2017 campaign
(EMCDDA, 2019), traces of SC were found in a high proportion
of the 1521 syringes collected from six sentinel European cities
(Amsterdam, Budapest, Glasgow, Helsinki, Lausanne, and Paris),
indicating that SC use among people who inject drugs is a
continuous phenomenon.
Injecting SC use was reported as a low-level and localized
incident in many European countries, except for Hungary and
Romania where a more substantial level of SC injecting was
observed. Injection of SC is of decisive relevance among those
who are injectors of other psychoactive substances, including
opioids and amphetamines (EMCDDA, 2015). Certain reports
denoted that long-term abstinent ex-opiate users shifted to SC
injecting (e.g., Van Hout and Bingham, 2012; Péterfi et al., 2014;
Rácz et al., 2015) throughout a time period of sustained heroin
shortage in the drug market. As part of this shift, clients of
OST started to abuse SC during their maintenance treatment
Abbreviations: 4-MEC, 4-methylethcathinone; BSI, Brief Symptom
Inventory; CERQ, Cognitive Emotion Regulation Questionnaire; CTQ-
SF, Childhood Trauma Questionnaire; GSI, Global Severity Index; MDPV,
3,4-methylenedioxypyrovalerone; mephedrone, 4-methylmethcathinone;
methylone, 3,4-methylenedioxy-N-methylcathinone; NPS, novel psychoactive
substance(s); OST, opioid substitution treatment; pentedrone, 2-(methylamino)-
1-phenylpentan-1-one; PTG, posttraumatic growth; PTSD, posttraumatic stress
disorder; SC, synthetic cathinone(s); SES, socioeconomic status; SUD, substance
use disorder(s); TTM, Transtheoretical Model; URICA, University of Rhode
Island Change Assessment Scale.
(Heikman et al., 2017; Kapitány-Fövény et al., 2017), explained by
either treatment deficiencies (inadequate dose of OST medicine),
easy SC availability or specific individual factors (e.g., severity of
psychiatric symptoms).
From a clinical perspective it is of high relevance to
understand the potential reasons of substance use during
treatment among OST clients, and more specifically to explore
whether or not these reasons differ by the substance being
consumed. The local phenomenon of opioid dependent
patients’ SC use enables the study of SC-specific consumption
determinants in a clinical sample. Of the many possible factors
underlying substance use during OST – e.g., shorter treatment
duration (Li et al., 2012), a medium 60–100 mg/day medication
dose (Baumeister et al., 2014), low treatment attendance, drug
using friends, family conflicts (Sullivan et al., 2014), male gender
(Vigna-Taglianti et al., 2016), younger age (Amiri et al., 2018),
or the quality and supportiveness of the social network (Shen
et al., 2018) – this paper focuses on the presumed impact of
unresolved childhood trauma, with special emphasis placed on
individual patterns of cognitive emotion regulation as related to
stressful live events.
Posttraumatic stress disorder frequently co-occurs with SUD.
An estimated prevalence of PTSD in SUD patients may range
from 25 to 49%, a three times higher prevalence than that
in the general population (Gielen et al., 2012). PTSD and
SUD may result in shared pathological features, such as
heightened stress sensitivity, reward deficiency or impulsive
behavior with overlapping impaired neurocircuitry (Enman et al.,
2014). Furthermore, as both pathologies can be interpreted
as the outcomes of hyperactivity to reminding cues, some
argues that PTSD and SUD are in fact disorders of memory
(Gisquet-Verrier and Le Dorze, 2019). Exposure to either stress
or psychoactive substances can induce epigenetic alterations
resulting in similar neurobiological, molecular and behavioral
changes (e.g., glucocorticoids can induce excitation patterns
by activating dopamine neurons) that facilitate drug-seeking
behavior (Pizzimenti and Lattal, 2015). However, experiencing
traumatic events does not necessarily lead to PTSD. Emotion
regulation – connected to cognitive processes – helps the
individual in recognizing, evaluating and influencing the course
and expression of emotions (Domaradzka and Fajkowska, 2018).
Posttraumatic cognitive emotion regulation plays an important
mediatory role in the relationship between trauma and either
PTSD or PTG. For instance, intrusive rumination might be
associated with PTSD, while deliberate rumination can be linked
to PTG (Zhang et al., 2018), indicating different cognitive
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processes in case of negative or positive trauma outcomes,
even if PTSD and PTG may also coexist on an individual
level. Similarly, while some forms of cognitive processes
are thought to be unproductive (e.g., overgeneralization,
avoidance), there are many constructive ways (e.g., decentering,
accommodation of corrective information) of trauma processing
(Hayes et al., 2017).
Regarding the subpopulation of OST clients, early childhood
trauma has been linked to poorer treatment retention in OST
programs (Kumar et al., 2016), childhood sexual abuse was
found to be a predictor of drug use during OST (Schiff et al.,
2010), while NPS use among treatment seeking opioid dependent
patients was evaluated as an attempt of self-medication for earlier
psychological trauma (Gittins et al., 2018). Additionally, OST
patients with a history of childhood trauma show impaired ability
to associate a stimulus with its outcome when the stimuli is
presented in a drug-related context (Weiss et al., 2019), hence
clients’ cognitive efficacy might be reduced by drug-related
stimuli. Cues that are associated with either stress or drugs also
increase opioid craving and anxiety (Hyman et al., 2007) and pose
negative impact on OST prognosis (Jaremko et al., 2015).
As regards SC use among OST clients, the subgroup of patients
who consume any SC during treatment is characterized by
younger age, shorter treatment duration, more severe psychiatric
symptoms and higher stress reactivity to interpersonal conflicts
(Kapitány-Fövény et al., 2017). Based on these previous findings,
the current study aimed to assess whether OST clients with and
without a history of SC use during treatment differ in experienced
childhood trauma, cognitive emotion regulation strategies (i.e.,
how they cope with stressful life events), the severity of their
psychiatric symptoms, their motivation for behavioral change
and the rate of treatment retention.
MATERIALS AND METHODS
Procedure
A total of 206 clients of Hungary’s biggest drug outpatient centers
(Nyírõ Gyula National Institute of Psychiatry and Addictions,
Budapest) OST were involved in the study. Data collection was
implemented by face-to-face interviews conducted by trained
psychologists. Inclusion criteria were: (1) being a client of
either methadone or Suboxone (a combination formulation
of buprenorphine and naloxone) maintenance therapy for at
least 1 year, (2) 18 < years of age, (3) signing the informed
consent form; while exclusion criteria were: (1) acute drug
effects, (2) agitation or violent behavior. After eight patients
were excluded from the study, the final sample consisted of
198 participants. In order to prevent respondents from being
influenced by the acute sedative effects of OST medication, data
was collected just before the administration of either methadone
or buprenorphine-naloxone.
Baseline data was collected in the summer of 2015, while
follow-up data on treatment retention was obtained in the
summer of 2019 (4 years follow up).
Ethical approval was provided by the hospital’s Research
Ethics Committee.
Measures
Demographics and Treatment Characteristics
Demographic items were comprised of questions regarding
gender, age, educational background, marital status, perceived
SES and occupation. Perceived SES was measured by a
7-point Likert scale (from 1 = the lowest possible SES to
7 = the highest possible SES). Treatment indices included the
length of treatment, the type of OST medication (methadone
vs. buprenorphine-naloxone) and medication dose. The
following rule-breaking behaviors were also explored: buying
street methadone/buprenorphine-naloxone, intravenous
administration of methadone/buprenorphine-naloxone.
Synthetic Cathinone Use
Participants provided information about their past year and past
month SC use experiences during OST. Mephedrone, pentedrone
and MDPV as the most prevalent SC in Hungary were listed in
the questionnaire.
Childhood Trauma
Childhood traumatic experiences (CTQ) were assessed by the
short form of the CTQ-SF. CTQ-SF is a retrospective recall based
measure (Bernstein et al., 2003), containing 28 items of which
three are validity items. The remaining 25 clinical items load
on five factors: (1) Emotional abuse (e.g., “Family said hurtful
things”), (2) Physical abuse (e.g., “Punished with hard objects”),
(3) Sexual abuse (e.g., “Was sexually abused”), (4) Emotional
neglect (e.g., the reversed item of “Made to feel important,”
(5) Physical neglect (e.g., “Not enough to eat”). Respondents
evaluate each statement by using a 5-point Likert scale (from
0 = never to 4 = very often).
Good reliability was found regarding the five factors, with the
following Cronbach’s α scores: Emotional abuse = 0.89, Physical
abuse = 0.92, Sexual abuse = 0.94, Emotional neglect = 0.95,
Physical neglect = 0.87.
Cognitive Emotion Regulation
The short 18-item version of the CERQ (Garnefski and Kraaij,
2006; Miklósi et al., 2011) was applied to measure subjects’ stress-
related cognitive-affective processing style. The short form of
the CERQ comprises of nine conceptual scales: (1) Self-blame
(e.g., “I feel that I am the one to blame for it”), (2) Other-blame
(e.g., “I feel that others are responsible for what has happened”),
(3) Rumination (e.g., “I dwell upon the feelings the situation has
evoked in me”), (4) Catastrophizing (e.g., “I continually think
how horrible the situation has been”), (5) Positive refocusing
(e.g., “I think about pleasant experiences”), (6) Refocus on
planning (e.g., “I think about how to change the situation”),
(7) Positive reappraisal (e.g., “I think I can learn something from
the situation”), (8) Putting into perspective (e.g., “I think that
it all could have been much worse”) and (9) Acceptance (e.g.,
“I think that I have to accept the situation”), with two items per
scale. The questionnaire’s items are evaluated on a 5-point Likert
scale (from 1 = almost never to 5 = almost always). The higher
the subscale score, the more inherent the cognitive strategy is.
CERQ’s conceptual scales are additionally interpreted as either
adaptive (Positive refocusing, Planning, Positive reappraisal,
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Putting into perspective and Acceptance) or non-adaptive (Self-
blame, Other-blame, Rumination, Catastrophizing) strategies.
With regard to reliability testing, the following good,
acceptable or low Cronbach’s α scores were found for the nine
scales: Self-blame = 0.63, Other-blame = 0.72, Rumination = 0.83,
Catastrophizing = 0.82, Positive refocusing = 0.68, Refocus
on planning = 0.63, Positive reappraisal = 0.62, Putting into
perspective = 0.53, Acceptance = 0.67.
Motivation for Behavior Change
Respondents’ current motivational state regarding a potential
decision to change their substance use habits (e.g., stop using
any psychoactive substances during treatment or reducing their
OST medication dose) was measured by the 32-item version of
the URICA (DiClemente and Hughes, 1990). URICA is based
on the TTM of behavioral change (Prochaska and DiClemente,
1983) and as such theoretically driven measure, contains the
following subscales: (1) Precontemplation (e.g., “I’m not the
problem one. It doesn’t make much sense for me to consider
changing”), (2) Contemplation (e.g., “I’ve been thinking that I
might want to change something about myself ”), (3) Action (e.g.,
“I am really working hard to change”) and (4) Maintenance (e.g.,
“I’m struggling to prevent myself from having a relapse of my
problem”). Readiness to change as a second-order factor is yielded
by using the formula: Contemplation + Action +Maintenance -
Precontemplation.
Responses are given on a 5-point Likert scale (from
1 = strongly disagree to 5 = strongly agree).
In the current study, the following low or good
Cronbach’s α scores were observed: Precontemplation = 0.53,
Contemplation = 0.49, Action = 0.79, Maintenance = 0.73.
Psychiatric Symptoms
Current (last week’s) psychiatric symptoms were assessed by the
BSI (Derogatis, 1975; Urbán et al., 2014). The 53 items of the
BSI are evaluated by using a 5-point Likert scale (from 0 = not
at all to 4 = extremely). BSI comprises nine symptom scales:
(1) Somatization (e.g., “Pain on heart or chess”), (2) Obsession-
compulsion (e.g., “Feeling blocked in getting things done”), (3)
Interpersonal sensitivity (e.g., “Your feeling being easily hurt”),
(4) Depression (e.g., “Feeling lonely”), (5) Anxiety (e.g., “Feeling
tense or keyed up”), (6) Hostility (e.g., “Getting into frequent
arguments”), (7) Phobic anxiety (e.g., “Feeling afraid to travel on
buses, subways or trains”), (8) Paranoid ideation (e.g., “Feeling
that you are watched or talked about by others”) and Psychoticism
(e.g., “The idea that something is wrong with your mind”). A GSI
was computed as the mean of the 53 items.
Good or acceptable reliability results were found: Cronbach’s
α scores regarding the nine scales were: Somatization = 0.87,
Obsession-compulsion = 0.8, Interpersonal sensitivity = 0.73,
Depression = 0.86, Anxiety = 0.85, Hostility = 0.82, Phobic
anxiety = 0.78, Paranoid ideation = 0.62, and Psychoticism = 0.66.
Urine Samples
As part of the OST protocol, clients were randomly screened for
the following substances by applying standard rapid urine tests:
opiate, cocaine, amphetamine, MDMA, THC, benzodiazepine.
Randomization was done by the hospital’s medical software as
based on clients’ Treatment Demand Indicator (TDI) codes.
Past year’s positive or negative test results were entered in our
database retrospectively. Since the outpatient centers urine tests
could not be used to detect SC, past year SC use was based on
respondents’ report only (see section “Synthetic Cathinone Use”).
Questionnaire data and urine test results were matched by clients’
TDI codes, however, in the final database only unique identifiers
were recorded in order to protect personality rights.
Statistical Analysis
Data were analyzed by SPSS 17 (SPSS Inc, 2008). Demographic
characteristics and treatment indices were explored by
descriptive statistics, potential differences between SC and
non-SC-using clients were analyzed by non-parametric Mann
Whitney U test and chi-square statistics, the association
between childhood trauma types and non-adaptive cognitive
emotion regulation strategies was tested by linear regression
model, while significant predictors of past year SC use and
treatment retention were identified by logistic regression models.
Participants were classified by their highest standardized z score
achieved on any of the BSI factors, referred to as “prominent
psychopathological dimension,” based on a very similar approach
presented by Maremmani et al. (2016). Psychopathological
symptom profiles were explored by using latent class analysis
in Mplus v5 (Muthén and Muthén, 1998–2007). Finally,
predictors of latent class memberships were examined by logistic
regression models.
RESULTS
Sample Characteristics
Table 1 summarizes detailed sample characteristics in terms of
demographics and treatment indices.
Clients with and without a history of past year SC use
were compared regarding demographic and treatment-related
variables. SC using clients were younger [SC-using: M = 37.1,
SD = 6.6, non-SC-using: M = 40.5, SD = 6.6, t(196) = 2.9,
p < 0.01], being in treatment for a shorter period of time [SC-
using: M = 5.1 years, SD = 6.1, non-SC-using: M = 7.4 years,
SD = 5.5, t(196) = 2.9, p < 0.01], showed lower rates (41.9
vs. 59.7%) of methadone/buprenorphine-naloxone street-buying
[χ2 (1, N = 177) = 4.2, p < 0.05] and lower rates (37.2 vs.
61.9%) of methadone/buprenorphine-naloxone injecting [χ2 (1,
N = 177) = 8.1, p < 0.01]. Lower rates (22.7%) of treatment
retention was observed among SC using OST clients [χ2 (1,
N = 198) = 5.2, p < 0.05] as compared to those without a
history of past year SC consumption (41.6%) at 4-years follow-up.
Clients receiving either methadone or buprenorphine-naloxone
were similarly compared in terms of their age, gender, years
spent in treatment, highest academic degree, SES, occupation,
taking other medication (e.g., benzodiazepine), rate of successful
dose reduction during treatment, IV use of OST medication, SC
use during treatment. Those receiving buprenorphine-naloxone
have spent less years in treatment [methadone clients: M = 7.2,
SD = 5.7, buprenorphine-naloxone clients: M = 3.6, SD = 4.5,
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TABLE 1 | Demographics and treatment characteristics.
Demographics
Age Mean (SD) 39.7 (6.8)
Gender distribution Male N (%) 141 (71.2)
Female N (%) 57 (28.8)
Educational background Elementary N (%) 52 (26.3)
Vocational/technical school N (%) 91 (46)
High school N (%) 28 (14.1)
Incomplete higher education N (%) 8 (4)
Completed higher education N (%) 19 (9.6)
Marital status Single N (%) 120 (60.6)
In a relationship N (%) 33 (16.7)
Married N (%) 24 (12.1)
Divorced N (%) 19 (9.6)
Widowed N (%) 2 (1)
Perceived socioeconomic status Mean (SD) 3.9 (1.1)
Occupation Unemployed N (%) 42 (21.2)
Temporary job N (%) 23 (11.6)
Permanent job N (%) 116 (58.6)
Maternity leave N (%) 2 (1)
Disability pension N (%) 14 (7.1)
Student N (%) 1 (0.5)
Treatment indices
Length of treatment Mean (SD) 6.9 (5.7)
Type of OST medication N (%) Methadone N (%) 178 (89.9)
Buprenorphine-naloxone N (%) 20 (10.1)
OST medication dose (mg) Methadone Mean (SD) 77.9 (33.8)
Buprenorphine-naloxone Mean (SD) 8.6 (5.5)
Buying street methadone/buprenorphine-naloxone N (%) 98 (49.5)
Intravenous administration of methadone/ 99 (50)
buprenorphine-naloxone N (%)
4 year treatment retention rate N (%) 74 (37.4)
TABLE 2 | Self-reported past year and past month SC use.
Past year Past month
Mephedrone N (% of full sample) 21 (10.7) 3 (1.5)
Pentedrone N (% of full sample) 36 (18.2) 10 (5.1)
MDPV N (% of full sample) 16 (8.1) 3 (1.5)
SC use in general N (% of the full sample) 44 (22) 12 (6.1)
t(198) = 3.4, p < 0.01], but did not differ from methadone clients
in any other measures.
Substance Use Profiles
Past month and past year SC use frequencies are presented
in Table 2.
In order to increase the sample size of SC using clients’
subgroup, we decided to merge distinct past year SC use
categories (mephedrone, pentedrone, MDPV) into one SC
category (N = 44) for further analyses. The overall sample
size of the merged subgroup was lower than the sum of the
three categories as some of the clients used more than one
SC derivative. Nevertheless, the most frequently used SC was
pentedrone among our OST clients. Intravenous SC use was
identified in a high proportion of past year SC users, with
altogether 28 participants (63.6%) reported SC injecting.
Last year use of opiate, cocaine, amphetamine, MDMA,
cannabis/hashish and the misuse of benzodiazepines during OST
was identified by urine test results. THC was found in 92
samples (46.5%), opiates in 86 (43.4%), benzodiazepine in 31
(15.7%), amphetamine in 19 (9.6%), MDMA in 8 (4%), and
cocaine in 6 (3%).
The current study also aimed to explore past year concurrent
substance use patterns during treatment. As self-reports were
based on a 1-year recall period, only urine samples were
able to provide objective measures regarding co-occurring
substance use. But since our study focuses on SC using clients,
Figure 1 presents the association between self-reported past
year SC use and urine sample-based concomitant substance use
profiles as well.
Past year SC use was mainly associated with opiate (n = 20)
and THC (n = 19) consumption in the same year, but not
necessarily in the same time period. Regarding concomitant
substance use patterns, opiates were most commonly co-
ingested with cannabis/hashish (53 clients concurrently used
these substances), while among those clients with a history of
past year SC use, the consumption of any other stimulants was
uncharacteristic. The co-occurrence of more than one stimulant
in the urine samples was also rare, indicating that OST clients
don’t often mix substances from the same drug class. There were
no significant differences in the rate of positive urine samples
between SC and non-SC-using clients.
Childhood Traumatic Experiences
Synthetic cathinone using and non-SC using OST clients were
compared regarding their CTQ. Table 3 summarizes the results
of comparative statistics.
Potential gender differences in the frequency of CTQ were also
analyzed, however, there were no significant differences between
males and females.
FIGURE 1 | Profile of past year’s concurrent substance use based on urine
test results and self-reports (in case of SC). SC, synthetic cannabinoids;
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol.
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TABLE 3 | Childhood traumatic experiences among OST clients with and without
a history of past year SC use.
SC use SC use not Mann
reported reported Whitney Effect
N = 44 N = 154 U test (U) size (r)
Emotional neglect Mean (SD) 4.1 (5.9) 5.6 (6.7) 2384.5 0.12
Emotional abuse Mean (SD) 2.7 (4.3) 3.8 (5.2) 2454 0.11
Physical abuse Mean (SD) 2.2 (3.9) 2.6 (4.6) 2832 0.05
Physical neglect Mean (SD) 0.7 (1.3) 2.5 (4.5) 2302.5* 0.26
Sexual abuse Mean (SD) 0.2 (0.7) 0.9 (3.2) 2820.5 0.15
*p < 0.05.
TABLE 4 | Cognitive emotion regulation related to stressful live events in SC and
non-SC using subgroups.
SC use SC use not Mann
reported reported Whitney Effect
N = 43 N = 133 U test (U) size (r)
Self-blame Mean (SD) 5.6 (1.9) 6.3 (2.3) 2381.5 0.17
Other-blame Mean (SD) 3.5 (1.4) 3.5 (1.5) 2747 0.00
Rumination Mean (SD) 5.6 (2) 5.9 (2.4) 2646.5 0.07
Catastrophizing Mean (SD) 4.2 (2.2) 4.5 (2.3) 2582 0.07
Positive refocusing Mean (SD) 4.1 (2.3) 4.3 (2.1) 2632 0.05
Refocus on planning Mean (SD) 5.9 (1.9) 6.9 (2) 2076.5** 0.25
Positive reappraisal Mean (SD) 6.6 (1.8) 7 (2.1) 2549 0.10
Putting into perspective Mean (SD) 5.9 (1.7) 6.1 (1.9) 2766.5 0.06
Acceptance Mean (SD) 5.8 (1.9) 6.1 (2.3) 2618 0.07
Adaptive strategies Mean (SD) 5.7 (1.2) 6.1 (1.4) 2343 0.15
Non-adaptive strategies Mean (SD) 4.7 (1.2) 5.1 (1.4) 2492 0.15
**p < 0.01.
Cognitive Emotion Regulation Strategies
As for cognitive emotion regulation strategies in the SC and
non-SC using subgroups, only one scale (Refocus on planning)
showed significant difference between these subgroups (Table 4).
Those clients without a past year history of SC use were
more prone to use planning as an adaptive strategy to cope
with stressful live situations. Refocus on planning as assessed by
the CERQ refers to thinking about potential ways to handle a
frustrating event.
The association between the type and frequency of endured
CTQ and non-adaptive cognitive emotion regulation strategies
were analyzed by regression models and compared by past year
SC use as a grouping variable. Figure 2 presents the results of the
two regression models.
In the non-SC-using subgroup, childhood physical neglect
showed significant association with non-adaptive cognitive
emotion regulation strategies, although only a low proportion
of the outcome variable’s variance was explained by the models
(R2 = 0.15 and 0.19).
Motivation to Change
In terms of motivation for behavior change, SC-using clients
were more likely to show higher scores on the precontemplation
domain of the URICA (Table 5).
This result indicates that SC-using clients might be less
motivated to change their substance use habits. This might also
be associated with lower treatment retention rates among SC-
using participants.
Psychiatric Symptom Profiles
Psychiatric symptoms were also measured and compared
between the two subgroups. Table 6 presents the results.
Synthetic cathinone-using OST clients showed higher scores
on almost every psychiatric symptom scales with the exception
of Somatization and Hostility. Furthermore, applying a 63 or
above GSI T (raw) score as cut-off for identifying cases of
clinical severity, a higher rate of screened psychiatric patients
were found among SC (N = 22, 53.7%) than non-SC-using
(N = 39, 25.7%) respondents [χ2 (1, N = 193) = 11.7, p < 0.01].
As a next step, participants were classified on the basis of
their prominent psychopathological dimension, according to
the highest standardized z score achieved on the BSI factors.
The three most dominant dimensions were depression (n = 51,
25.8%), somatization (n = 15.7%) and hostility (n = 19,
9.6%). Figure 3 presents the distribution of the dominant
psychopathological dimensions within the subgroups of SC-using
and non-SC-using respondents.
When compared, SC- and non-SC-using using subgroups
did not differ significantly in the rate of any prominent
psychopathological dimensions: Somatization [χ2 (1, N = 171) =
2.9, p > 0.05], Obsession-compulsion [χ2 (1, N = 171) = 0.3,
p > 0.05], Interpersonal sensitivity [χ2 (1, N = 171) = 1.8, p >
0.05], Depression [χ2 (1, N = 171) = 0.9, p > 0.05], Anxiety
[χ2 (1, N = 171) = 0.1, p > 0.05], Hostility [χ2 (1, N = 171) =
1.4, p > 0.05], Phobic anxiety [χ2 (1, N = 171) = 0.2, p >
0.05], Paranoid ideation [χ2 (1, N = 171) = 0.6, p > 0.05],
Psychoticism [χ2 (1, N = 171) = 3.8, p > 0.05]. Furthermore,
none of the dominant psychopathological dimensions showed
significant association with treatment retention rates, indicating
that psychiatric subtypes among OST clients might not differ in
their treatment outcomes.
A person-centered approach was also applied in order
to examine potential latent classes of users regarding their
psychopathological profile based on achieved BSI factor scores.
Latent profile analysis is a form of latent variable analyses (e.g.,
Collins and Lanza, 2010) with categorical latent variable and
continuous manifest indicators (in this case the BSI factor scores).
The Bayesian information criteria parsimony index (BIC),
entropy and the interpretability of clusters were used during
the process of determining the number of latent classes. Lower
BIC value and higher value of entropy are preferable in model
selection. The determination of the number of classes is usually
supported by the results of the likelihood-ratio difference test
[Lo–Mendell–Rubin adjusted likelihood-ratio test (LRT)], which
compares the estimated model with a model of one less class
(k - 1). In this case low p value (p< 0.05) indicates that the model
with one less class is rejected in favor of the estimated model,
however, none of our tested models yielded significant LRT
test, therefore final model determination was based on BIC and
entropy values. One- (BIC = 121420.8), two- (BIC = 123256.6),
three- (121481.3), and four-class (BIC = 121534.1) solutions were
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FIGURE 2 | The variability of non-adaptive cognitive emotion regulation strategies explained by childhood traumatic experiences among SC and non-SC-using
clients. ∗p < 0.05; unstandardized B coefficients are presented with standard errors (in brackets). SC, synthetic cannabinoids; CER, cognitive emotion regulation.
estimated throughout the analysis. Entropy increased at two-class
(0.887), reached its peak at three-class (0.947) and decreased
at four-class solution (0.483). Finally, a three-class solution was
accepted. Figure 4 presents the psychiatric symptom profiles of
the three classes.
Based on their most likely latent class membership,
111 participants belonged to the first class (less severe
symptomatology), 57 participants to the second class (moderate
symptom severity), while 25 respondents belonged to the
third class (most severe symptomatology). These symptom
profiles differ in their global severity but not in the pattern
of dominant psychopathologies, indicating that OST clients
might be similar in terms of psychiatric symptom patterns. SC
using clients were more likely to belong to either the second
(n = 16, 39%) or the third class (n = 8, 19.5%) than non-SC-using
participants (second class: n = 41, 27%, third class: n = 17, 11.2%)
TABLE 5 | Stages of motivation for behavior change in SC and non-SC using OST
clients.
SC use SC use not Mann
reported reported Whitney Effect
N = 42 N = 132 U test (U) size (r)
Precontemplation Mean (SD) 18.6 (5.9) 16.6 (4.9) 2200.5* 0.18
Contemplation Mean (SD) 30.4 (5.1) 30.7 (7.5) 2845 0.02
Action Mean (SD) 30.1 (6.9) 30.7 (5.9) 2764.5 0.05
Maintenance Mean (SD) 27.6 (6.3) 28.6 (6.9) 2558 0.08
Readiness to change Mean (SD) 17.4 (4.3) 18.3 (4.2) 2416 0.11
*p < 0.05.
[χ2 (1, N = 193) = 5.5, p< 0.05]. Clients receiving methadone vs.
buprenorphine-naloxone did not differ in the rate of their class
memberships [χ2 (1, N = 193) = 1.4, p > 0.05]. Additionally,
there were no differences in treatment retention rates between
the members of the three latent classes (the retention rates
for the first, second and third class were 38.7, 42.1, and 24%,
respectively) [χ2 (2, N = 193) = 2.5, p > 0.05].
Finally, class membership was predicted by using logistic
regression analysis, entering treatment indices and SC use during
treatment as covariates in the model. Table 7 summarizes the
result of these analyses. The only significant predictor was SC
use during treatment regarding first latent class membership,
TABLE 6 | Psychiatric symptoms of SC and non-SC using subgroups.
SC use SC use not Mann
reported reported Whitney Effect
N = 43 N = 154 U test(U) size (r)
Somatization Mean (SD) 1.3 (1.1) 1.1 (0.9) 2990 0.09
Obsession-Compulsion Mean (SD) 1.4 (0.9) 0.9 (0.8) 2250** 0.28
Interpersonal Sensitivity Mean (SD) 1.4 (1.1) 0.8 (0.8) 2299** 0.29
Depression Mean (SD) 1.8 (1.3) 1.2 (0.9) 2492* 0.26
Anxiety Mean (SD) 1.5 (0.9) 0.9 (0.9) 2357.5** 0.32
Hostility Mean (SD) 1.1 (1.1) 0.8 (0.9) 2594.5 0.15
Phobic Anxiety Mean (SD) 1.2 (1.1) 0.7 (0.8) 2599.5* 0.25
Paranoid Ideation Mean (SD) 1.3 (0.8) 0.9 (0.7) 2271.5** 0.26
Psychoticism Mean (SD) 0.9 (0.9) 0.5 (0.6) 2467*** 0.25
Global Severity Index Mean (SD) 1.3 (0.9) 0.9 (0.7) 2220** 0.24
*p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3 | Distribution of prominent psychopathological dimensions with and without reported SC use. SC, synthetic cannabinoids.
indicating that treatment indices (such as OST medication type,
dose, years in treatment or receiving other medication such as
benzodiazepines) do not show significant association with the
severity of psychiatric symptom profiles. Those clients, however,
who used SC during treatment had lower odds of belonging to
the less severe psychiatric symptom class.
Predictors of SC Use
In order to examine the association between past year SC use and
those variables that resulted in significant differences between
SC-using and non-SC-using subgroups, a logistic regression
model was tested (Table 8).
Clients with more severe psychiatric symptoms showed
elevated risk for past year SC use (OR = 2.03), while those
who spent longer time in treatment had lower odds of SC
consumption (OR = 0.91).
Predictors of Treatment Retention
Finally, a logistic regression model was applied to test
potential explanatory variables of treatment retention.
Besides SC use, explanatory variables (age, gender, years in
treatment, OST medication dose) were selected as commonly
reported factors associated with treatment retention. Table 9
summarizes the results.
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FIGURE 4 | Latent profiles of psychiatric symptom severities.
Past year SC use was the only significant predictor in
the model, associated with decreased treatment retention
odds (OR = 0.44).
DISCUSSION
Our study indicated differences between OST clients with
and without a history of past year SC use in terms of
treatment indices, childhood trauma experiences, cognitive
emotion regulation strategies, motivation for behavior change
and psychiatric symptom severity.
As regards treatment indices, the result that SC-using
clients were less likely to buy street methadone/buprenorphine-
naloxone as well as to inject their OST medication can
primarily be explained by the assumption that instead of
misusing/overusing opioid medication they are more prone
to use SC in order to experience euphoria during treatment.
Clients receiving buprenorphine-naloxone have spent less years
in treatment than those who were taking methadone. This
finding might be attributed to the fact that Suboxone was only
introduced in 2007 in Hungary (Demetrovics et al., 2009), and
further years have passed until clinicians started to prescribe
this medication instead of methadone as a first-line OST
medication. The buprenorphine-naloxone clients participating
in this study were most likely among the first new clients
who started their OST treatment with buprenorphine-naloxone
and not methadone. Within the scope of the current study
clients receiving methadone or buprenorphine-naloxone did not
differ in any further measures. 4-year retention rate among
non-SC-using clients (41.6%) was relatively high as compared
to previous findings that identified a 18 months retention
rate of 32.3% (Lin et al., 2013), a 1-year retention rate of
34.4% (Sheikh Fathollahi et al., 2016) or a 3-year retention rate
of 20% (Yang et al., 2013) among OST clients, although some
reported much higher, 87% 1-year retention rate (Jiang et al.,
2014) or a 57% retention rate at 4-years follow-up (Wei et al.,
2013). Past year SC use was associated with higher proportion
of treatment drop-outs. Given the finding that almost every
second client was screened positive for past year cannabis or
opiate use during treatment and considering that there were no
significant differences in the rate of positive urine test results
between SC and non-SC-using clients, it might be assumed that
SC use per se is a significant risk factor for drop-out. This
assumption was further supported by the results of the second
logistic regression model, namely that past year’s SC use was a
significant predictor of reduced treatment retention. SC using
OST clients had approximately two times higher risk of drop
out. In contrast to previous findings, age, gender, years spent in
treatment or the dose of methadone or buprenorphine-naloxone
did not show significant association with treatment retention.
SC users were more likely to be in the precontemplation stage
of behavior change, showing limited or no motivation to stop
using psychoactive substances. Therefore frequent screening of
clients’ current motivation for behavior change should be an
important routine in addiction care and especially in low-
threshold services such as OST programs, accompanied by
motivational interviewing.
Childhood physical neglect was related to non-adaptive
cognitive emotion regulation strategies among non-SC-using
clients. Previous results indicate that childhood neglect may
predict deficits in the recognition of positive emotions (Young
and Widom, 2014), that might explain difficulties in applying
adaptive strategies, such as refocus on planning, positive
reappraisal or putting a stressful life event into a more acceptable
perspective. On a neurobiological level, others found that right
amygdale volume mediates the association between neglect and
anxiety (Roth et al., 2018) or that early exposure to either
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TABLE 7 | Treatment indices and SC use during treatment as predictors of latent
class memberships.
Odds
B (SE) p ratio 95% CI
Class 1 membership R2 = 0.052 (Cox and Snell),
0.070 (Nagelkerke), N = 173
OST medication dose −0.01-(0.01) 0.671 0.99 0.99, 1.01
Years in treatment −0.04-(0.03) 0.154 0.96 0.90, 1.02
OST medication: methadone
vs. buprenorphine-naloxone
−0.97-(0.64) 0.129 0.38 0.11, 1.33
Receiving other medication
(e.g., benzodiazepines)
−0.23-(0.32) 0.478 0.79 0.42, 1.51
SC use during treatment −0.94-(0.39) 0.018 0.39 0.18, 0.85
Class 2 membership R2 = 0.036 (Cox and Snell),
0.051 (Nagelkerke), N = 173
OST medication dose −0.00-(0.01) 0.916 0.99 0.99, 1.01
Years in treatment 0.02-(0.03) 0.472 1.02 0.96, 1.09
OST medication: methadone
vs. buprenorphine-naloxone
0.84-(0.65) 0.196 2.32 0.65, 8.29
Receiving other medication
(e.g., benzodiazepines)
0.43-(0.35) 0.220 1.54 0.77, 3.08
SC use during treatment 0.67-(0.41) 0.100 1.94 0.88, 4.29
Class 3 membership R2 = 0.023 (Cox and Snell),
0.045 (Nagelkerke), N = 173
OST medication dose 0.01-(0.01) 0.470 1.01 0.99, 1.02
Years in treatment 0.05-(0.05) 0.269 1.05 0.96, 1.15
OST medication: methadone
vs. buprenorphine-naloxone
0.27-(0.99) 0.783 1.31 0.19, 9.05
Receiving other medication
(e.g., benzodiazepines)
−0.32-(0.48) 0.513 0.73 0.28, 1.88
SC use during treatment 0.71-(0.54) 0.189 2.04 0.70, 5.91
Significant explanatory variables and related values are boldfaced. CI,
confidence interval.
TABLE 8 | Logistic regression model to test the retrospective odds for past year
SC use.
Odds
B (SE) p ratio 95% CI
R2 = 0.179 (Cox and Snell), 0.271 (Nagelkerke), N = 168
Age −0.05-(0.03) 0.142 0.95 0.89, 1.02
Years in treatment −0.09-(0.04) 0.034 0.91 0.84, 0.99
Childhood physical neglect (CTQ) −0.15-(0.09) 0.090 0.86 0.72, 1.03
Refocus on planning (CERQ) −0.16-(0.10) 0.104 0.85 0.69, 1.03
Precontemplation (URICA) 0.06-(0.04) 0.133 1.06 0.98, 1.14
Global Severity Index (BSI) 0.71-(0.29) 0.014 2.03 1.16, 3.56
Significant explanatory variables and related values are boldfaced. CI,
confidence interval.
emotional or physical neglect is related to amygdala hypertrophy
and mood disorders (Herzog and Schmahl, 2018). Increased risk
for anxiety and mood disorders thus further reduce the capability
to focus on positive outcomes in stressful live situations. Non-
SC-using clients reported a more frequent exposure to physical
neglect in their childhood, denoting that SC use is probably not
a maladaptive self-medication attempt in terms of dealing with
early trauma experiences.
TABLE 9 | A logistic regression model to predict treatment retention.
Odds
B (SE) p ratio 95% CI
R2 = 0.056 (Cox and Snell), 0.057 (Nagelkerke), N = 198
Age −0.02-(0.03) 0.465 0.98 0.94, 1.03
Gender −0.25-(0.35) 0.477 0.78 0.39, 1.54
Years in treatment −0.05-(0.03) 0.093 1.05 0.99, 1.11
OST medication dose −0.01-(0.01) 0.253 1.01 0.99, 1.01
SC use during treatment −0.82-(0.42) 0.049 0.44 0.19, 0.99
Significant explanatory variables and related values are boldfaced. CI,
confidence interval.
Approximately half of SC-using clients were characterized
by psychiatric symptoms of clinical severity, and global severity
of these symptoms was a significant explanatory variable of
SC use during treatment. Considering the identified latent
profiles of psychiatric symptom severities, none of the treatment
indices could predict class memberships, however, SC use during
treatment was significantly associated with lower odds to belong
to the less severe class of psychiatric symptoms. Prominent
psychopathological dimensions were additionally examined. Our
result that the most dominant psychopathologies of opioid-
dependent clients are depression, somatization and hostility
is in line with former findings, including the self-medication
hypothesis of Khantzian (1985) that highlights the powerful
muting action of opiates on the threatening affect of aggression.
OST clients might also use or misuse their medication as a form
of maladaptive self-medication in order to ease their depressive
symptoms and violent urges. These findings emphasize the
importance of psychiatric screening among OST clients in order
to identify patients with potential unrecognized dual diagnoses.
On the other hand, unlike Maremmani et al. (2016) we could not
identify any significant associations between treatment outcomes
and prominent psychopathological subtypes. Nevertheless, as
other authors have already pointed out (e.g., Schulte et al., 2010),
unidentified comorbid disorders may increase the risk of drop-
out from addiction treatment, yet psychiatric comorbidity often
remains a latent factor. Another related anomaly also needs to
be addressed: according to the results of McGovern et al. (2014),
only a minority of addiction treatment programs is capable of
providing integrated services. Hence, public access to integrated
care should be increased. A possible solution for enhancing the
efficacy of dual diagnosis recognition would be the synthesis
of addiction/psychiatry and primary care services, stressing the
role of GPs and community services in early identification
of both addiction problems (among other things, anamnestic
information about SC or NPS use in general) and co-occurring
mental disorders, including PTSD as well.
Limitations
The current study is not without limitations. While past year’s
opiate, cocaine, amphetamine, MDMA, THC or benzodiazepine
misuse were described by positive urine test results as objective
measures, SC use was based on clients’ self-reports. Furthermore,
past year’s SC use as a retrospective and self-reported measure
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was predicted by variables that were subsequently assessed
(e.g., GSI). In these cases, a relative persistence was assumed
regarding the values of explanatory variables, however, this is
not necessarily realistic as the severity of psychiatric symptoms,
the motivation for behavior change or the current cognitive
emotion regulation strategies may markedly change over a time-
span of 1 year. As regards our statistical analyses, only small –
or in some cases medium – effect sizes were found, as based
on Cohen’s rule of thumb. Childhood traumatic experiences
were also assessed by clients’ retrospective self-reports, therefore
these results might have been impacted by potential recall biases.
Finally, OST clients’ psychiatric profiles assessed by BSI could
not be supported/confirmed by their clinical diagnoses as all
clients of the drug outpatient center received the exact same
comorbid diagnoses of opioid dependence (F11.20) and mixed
anxiety and depressive disorder (F41.2), most likely due to a
rather simplifying diagnostic procedure that mainly justifies the
applied pharmacotherapy but does not necessarily aim to provide
an elaborate psychopathological profile of the clients.
Future Directions
This study did not assess PTSD as a potential outcome of
childhood trauma, nor the mediatory role of psychiatric symptom
severity between trauma exposure and non-adaptive cognitive
emotion regulation strategies. These associations were partly
tested by others (e.g., Garnefski et al., 2017; McLaughlin and
Lambert, 2017; Karatzias et al., 2018), but not in a sample
of OST clients or in light of concurrent SC consumption.
Differences in emotion regulation and psychopathology between
SC-using clients and those who consume other stimulant drugs
(e.g., cocaine, amphetamine, MDMA) would highlight further
specificities of SC regarding the consecutive neuropsychological
traits of its use.
CONCLUSION
Synthetic cathinone use is a risk factor of poorer treatment
outcomes, characterized by more severe psychiatric symptoms
as well as a lack of motivation to change substance use
behavior among opioid dependent clients. The availability of
rapid urine tests able to detect NPS like SC need to be
increased in order to more efficiently screen OST clients’ SC
consumption during therapy.
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